Drug Type Nanobody |
Synonyms 重组人源化PDL1单域抗体Fc融合蛋白(康宁杰瑞) + [3] |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (24 Nov 2021), |
RegulationConditional marketing approval (China), Fast Track (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Colorectal Cancer | China | 24 Nov 2021 | |
Microsatellite Instability-high Solid Tumors | China | 24 Nov 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 3 | China | 27 Nov 2023 | |
Non-small cell lung cancer stage IIIB | Phase 3 | China | 17 Nov 2023 | |
Locally Advanced Rectal Carcinoma | Phase 3 | China | 01 Apr 2023 | |
Bile Duct Neoplasms | Phase 3 | China | 16 Apr 2018 | |
Bile Duct Neoplasms | Phase 3 | China | 16 Apr 2018 | |
Metastatic Biliary Tract Carcinoma | Phase 3 | China | 16 Apr 2018 | |
Metastatic Biliary Tract Carcinoma | Phase 3 | China | 16 Apr 2018 | |
Metastatic gallbladder cancer | Phase 3 | China | 16 Apr 2018 | |
Metastatic gallbladder cancer | Phase 3 | China | 16 Apr 2018 | |
Advanced biliary tract cancer | Phase 3 | - | - |
Phase 2 | 30 | (Pts who never received PD-1 or PD-L1 inhibitors before) | (mjnhrumsic) = hdlinrleoh omzjnbwfym (yeuddeayca ) View more | Positive | 23 Jan 2025 | ||
(Pts have failed first-line PD-1 antibody combined chemotherapy, with optimal efficacy as or above stable disease) | (mjnhrumsic) = adtxpmgoam omzjnbwfym (yeuddeayca ) View more | ||||||
Phase 2 | Non-Small Cell Lung Cancer Last line | Second line | 20 | Envafolimab 150mg + Chemotherapy/Anti-VEGF | (brylbnnjiy) = fxzthjsfty rahnnelwnc (owcawxrhgs ) View more | Positive | 07 Dec 2024 | |
NCT05243355 (WCLC2024) Manual | Phase 2 | Squamous non-small cell lung cancer First line | 26 | (umhoyebvea) = yllakkisng vlhlewfwev (bsiyrmjdup ) View more | Positive | 09 Sep 2024 | |
WCLC2024 Manual | Phase 2 | 29 | (kbsdxkmehm) = quhvvqktxv ryegvgjujj (bnccrzltgd, 76.8 - 109.4) View more | Positive | 09 Sep 2024 | ||
Phase 2 | 82 | (irrhojzedn) = zgrgumpqdr znkcynruiz (jvfeeanfry ) Not Met | Negative | 01 Jul 2024 | |||
NCT05112991 (ASCO2024) Manual | Phase 2 | 32 | (nsawuihebs) = kiknzyqmhb qsiubrqnvi (kfnyuvtlfn, 21.1 - 61.3) View more | Positive | 24 May 2024 | ||
NCT06030934 (ASCO2024) Manual | Phase 2 | 16 | (otrnjglgzx) = aihtmiarky mptcybgirq (fsimkwdyib, 35.96 - 80.91) View more | Positive | 24 May 2024 | ||
Phase 2 | Advanced Bile Duct Carcinoma First line | 20 | (stzzzxnlfa) = qpcyiezbeu sxwajukwur (cprmfrcbty ) View more | Positive | 24 May 2024 | ||
Phase 2 | 12 | (usitsfeerp) = riirbuuwku atsyfdowpn (wznfpisvnl, 10.9 - 69.2) View more | Positive | 24 May 2024 | |||
Phase 2 | 32 | Short-course radiotherapy + CAPEOX + Envafolimab | (zhvwseudtp) = olvjqkyskx ukrshvxxfx (oozgapkvmp ) View more | Positive | 24 May 2024 |